These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 12901341)

  • 1. CMML: a biologically distinct myeloproliferative disease.
    Cortes J
    Curr Hematol Rep; 2003 May; 2(3):202-8. PubMed ID: 12901341
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chronic myelomonocytic leukemia: myeloproliferative variant.
    Onida F; Beran M
    Curr Hematol Rep; 2004 May; 3(3):218-26. PubMed ID: 15087071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic myelomonocytic leukemia: lost in classification?
    Bowen DT
    Hematol Oncol; 2005 Mar; 23(1):26-33. PubMed ID: 16149105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chronic neutrophilic leukemia and chronic myelomonocytic leukemia: WHO defined.
    Elliott MA
    Best Pract Res Clin Haematol; 2006; 19(3):571-93. PubMed ID: 16781489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myelodysplastic and myeloproliferative disorders in children.
    Hasle H
    Curr Opin Pediatr; 2007 Feb; 19(1):1-8. PubMed ID: 17224655
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
    Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
    Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Juvenile myelomonocytic leukemia and chronic myelomonocytic leukemia.
    Emanuel PD
    Leukemia; 2008 Jul; 22(7):1335-42. PubMed ID: 18548091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia.
    Bacher U; Haferlach T; Schnittger S; Kreipe H; Kröger N
    Br J Haematol; 2011 Apr; 153(2):149-67. PubMed ID: 21401573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myelomonocytic leukaemia (CMML)--a myelodysplastic or myeloproliferative syndrome?
    Michaux JL; Martiat P
    Leuk Lymphoma; 1993 Jan; 9(1-2):35-41. PubMed ID: 8477199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
    Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
    Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chronic myelomonocytic leukemia (CMML): recent advances in molecular pathogenesis and treatment].
    Harada Y; Harada H
    Rinsho Ketsueki; 2016 Feb; 57(2):147-55. PubMed ID: 26935632
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutting the cord from myelodysplastic syndromes: chronic myelomonocytic leukemia-specific biology and management strategies.
    Padron E; Steensma DP
    Curr Opin Hematol; 2015 Mar; 22(2):163-70. PubMed ID: 25575034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sensitivity to imatinib but low frequency of the TEL/PDGFRbeta fusion protein in chronic myelomonocytic leukemia.
    Gunby RH; Cazzaniga G; Tassi E; Le Coutre P; Pogliani E; Specchia G; Biondi A; Gambacorti-Passerini C
    Haematologica; 2003 Apr; 88(4):408-15. PubMed ID: 12681968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical importance of bone marrow monocytic nodules in patients with myelodysplasia: retrospective analysis of 21 cases.
    Chen YC; Chou JM; Letendre L; Li CY
    Am J Hematol; 2005 Aug; 79(4):329-31. PubMed ID: 16044436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The WHO classification of the myelodysplastic syndromes.
    Bain B
    Exp Oncol; 2004 Sep; 26(3):166-9. PubMed ID: 15494682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management.
    Parikh SA; Tefferi A
    Am J Hematol; 2012 Jun; 87(6):610-9. PubMed ID: 22615103
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders.
    Cortes J; Kantarjian H
    Cancer; 2004 May; 100(10):2064-78. PubMed ID: 15139047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia.
    Cervera N; Itzykson R; Coppin E; Prebet T; Murati A; Legall S; Vey N; Solary E; Birnbaum D; Gelsi-Boyer V
    Am J Hematol; 2014 Jun; 89(6):604-9. PubMed ID: 24595958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survivin expression, apoptosis and proliferation in chronic myelomonocytic leukemia.
    Invernizzi R; Travaglino E; Benatti C; Malcovati L; Della Porta M; Cazzola M; Ascari E
    Eur J Haematol; 2006 Jun; 76(6):494-501. PubMed ID: 16529600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chronic myelomonocytic leukemia in the light of the WHO proposals.
    Germing U; Strupp C; Knipp S; Kuendgen A; Giagounidis A; Hildebrandt B; Aul C; Haas R; Gattermann N; Bennett JM
    Haematologica; 2007 Jul; 92(7):974-7. PubMed ID: 17606449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.